Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668324 · ClinicalTrials.gov registry record
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 134
- Enrollment target
NCT06668324 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 134 participants.
The verdict
NCT06668324 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 134 participants
- Enrollment target
Study Summary
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2025-09-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06668324
The ClinicalTrials.gov registry entry for NCT06668324 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06668324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06668324 about?
NCT06668324 is a clinical study titled "Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation". The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
What is the current status of trial NCT06668324?
This trial is currently completed. The enrollment target is 134 participants. The study started on 2024-11-15. Estimated completion is 2025-09-05.
Who is sponsoring clinical trial NCT06668324?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.